Vir Biotechnology (VIR) announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating
- Vir Biotechnology Poised for Growth: Buy Rating Reiterated Amid Clinical and Financial Advancements
- Vir Biotechnology price target raised to $31 from $26 at Barclays
- Vir Biotechnology’s Transformative Year: Earnings Call Insights
- Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue